Forma, Novartis in Protein Interaction Screening Deal

Jul 30, 2009

NEW YORK (GenomeWeb News) – Forma Therapeutics today said that it will collaborate with Novartis on screening drug candidates for oncology applications.

The Cambridge, Mass.-based firm said that it would utilize its cell-based screening platform to identify inhibitors for undisclosed protein-protein interaction targets. Financial and other terms of the alliance were not disclosed.

Steven Tregay, CEO of Forma, said that the alliance with Novartis "provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery."

Filed under

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.